Patient Demographics
| Characteristic | Cohort 1 | Cohort 2 |
|---|---|---|
| Vemurafenib 6 weeks (N = 38) | Vemurafenib 7–18 weeks (N = 15) | |
| Age (yr) | ||
| Mean (SD) | 48.6 (12.79) | 48.5 (13.90) |
| Median | 50.5 | 48.0 |
| Range | 21–73 | 26–67 |
| Gender – no. (%) | ||
| Male | 15 (39.5) | 6 (40.0) |
| Female | 23 (60.5) | 9 (60.0) |
| Race – no. (%) | ||
| White | 35 (92.1) | 15 (100.0) |
| Decline | 2 (5.3) | 0 (0.0) |
| Other | 1 (2.6) | 0 (0.0) |
| Metastasis stage – no. (%) | ||
| M1a | 9 (23.7) | 2 (13.3) |
| M1b | 13 (34.2) | 3 (20.0) |
| M1c | 16 (42.1) | 10 (66.7) |
| LDH level – no. (%) | ||
| ≤ ULN | 17 (44.7) | 5 (33.3) |
| > ULN | 17 (44.7) | 8 (53.3) |
| Not measured | 4 (10.5) | 2 (13.3) |
| Prior therapy – no. (%) | ||
| Surgery | 34 (89.5) | 13 (86.7) |
| Radiation | 7 (18.4) | 8 (53.3) |
| Chemotherapy | 4 (10.5) | 1 (6.7) |
| Anti-PD1/PDL1 | 0 | 0 |
| Mutation – no. (%) | ||
| BRAF | 38 (100.0) | 15 (100.0) |
| cKIT | 1 (2.6) | 0 (0.0) |
| Other | 1 (2.6) | 0 (0.0) |
| Performance Status | ||
| 0 | 24 (63.2) | 8 (53.3) |
| 1 | 14 (36.8) | 7 (46.7) |
Race of ‘Other’ had the description ‘Not specified’ recorded